Identification of biomarker and clarification of resistance mechanism in immune checkpoint inhibitor therapy

Identification of biomarker and clarification of resistance mechanism in immune checkpoint inhibitor therapy - IBIC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000027091

Enrollment

560

Registered

2017-04-24

Start date

2017-04-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer Kidney cancer Malignant melanoma Classical Hodgkin&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) 200 patients undergoing treatment with Nivolumab, Pembrolizumab, Atezolizumab, Durvalumab, or Ipilimumab among patients diagnosed with non-small cell lung cancer. (2) 100 patients undergoing treatment with Nivolumab with or without Ipilimumab or Pembrolizumab among patients diagnosed with kidney cancer. (3) 20 patients undergoing treatment with Ipilimumab, Nivolumab, or Pembrolizumab among patients diagnosed with malignant melanoma. (4) 10 patients undergoing treatment with Nivolumab among patients diagnosed with classical Hodgkin's lymphoma. (5) 30 patients undergoing treatment with Nivolumab or Pembrolizumab among patients diagnosed with head and neck cancer. (6) 50 patients undergoing treatment with Nivolumab among patients diagnosed with gastric cancer. (7) 100 patients undergoing treatment with Pembrolizumab among patients diagnosed with urothelial cancer. (8) 50 patients undergoing treatment with Pembrolizumab or Nivolumab among patients diagnosed with MSI-High solid tumor.

Exclusion criteria

Exclusion criteria: (1) Minor (2) Difficult to obtain consent

Design outcomes

Primary

Measure	Time frame
Clinical application to selection of patients to be applied for immunecheckpoint inhibitors or monitoring after treatment	—

Secondary

Measure	Time frame
Identification of new biomarkers	—

Countries

Japan

Contacts

Public ContactYuri Tomura

Kanagawa Cancer Center Cancer Vaccine and Immunotherapy Center

yuri-tomura@gancen.asahi.yokohama.jp045-520-2222

Outcome results